These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 25854397)
1. Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer. Wang B; Yu L; Yang GZ; Luo X; Huang L Asian Pac J Cancer Prev; 2015; 16(7):3003-7. PubMed ID: 25854397 [TBL] [Abstract][Full Text] [Related]
2. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Zhang Q; Hu G; Yang Q; Dong R; Xie X; Ma D; Shen K; Kong B Gynecol Oncol; 2013 Jul; 130(1):132-9. PubMed ID: 23623832 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer. Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570 [TBL] [Abstract][Full Text] [Related]
4. The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer. Lv XL; Zhu Y; Liu JW; Ai H Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5113-5116. PubMed ID: 28051260 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Kristjansdottir B; Levan K; Partheen K; Sundfeldt K Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789 [TBL] [Abstract][Full Text] [Related]
7. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. Wu J; Yin H; Zhu J; Buckanovich RJ; Thorpe JD; Dai J; Urban N; Lubman DM PLoS One; 2015; 10(3):e0121112. PubMed ID: 25799488 [TBL] [Abstract][Full Text] [Related]
8. Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer. Xing BL; Li T; Tang ZH; Jiao L; Ge SM; Qiang X; OuYang J Genet Mol Res; 2015 May; 14(2):4532-40. PubMed ID: 25966226 [TBL] [Abstract][Full Text] [Related]
9. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis. Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831 [TBL] [Abstract][Full Text] [Related]
10. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial ovarian cancer patients. Bastani A; Asghary A; Heidari MH; Karimi-Busheri F Eur J Gynaecol Oncol; 2017; 38(3):418-424. PubMed ID: 29693884 [TBL] [Abstract][Full Text] [Related]
12. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer. Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000 [TBL] [Abstract][Full Text] [Related]
13. Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer. Wu X; Li D; Liu L; Liu B; Liang H; Yang B Arch Gynecol Obstet; 2014 Jun; 289(6):1309-14. PubMed ID: 24370956 [TBL] [Abstract][Full Text] [Related]
14. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer. Zou L; He X; Zhang JW Braz J Med Biol Res; 2010 Dec; 43(12):1232-8. PubMed ID: 21103788 [TBL] [Abstract][Full Text] [Related]
15. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses. Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232 [TBL] [Abstract][Full Text] [Related]
16. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women. Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y Tumour Biol; 2016 Feb; 37(2):2183-91. PubMed ID: 26349751 [TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts. Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055 [TBL] [Abstract][Full Text] [Related]
18. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer. Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum CCL18 as a potential biomarker for ovarian cancer. Yuan L; Wan J; Huang C; Liang J; Liu M; Yue C; Li L Cancer Biomark; 2017 Dec; 21(1):97-104. PubMed ID: 29036787 [TBL] [Abstract][Full Text] [Related]
20. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer. Pearl ML; Zhao Q; Yang J; Dong H; Tulley S; Zhang Q; Golightly M; Zucker S; Chen WT Gynecol Oncol; 2014 Sep; 134(3):581-90. PubMed ID: 24972191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]